Alivus Life Sciences Limited has announced its quarterly earnings call to discuss the financial performance for Q3 FY2025-26. The pharmaceutical company, formerly known as Glenmark Life Sciences Limited, has scheduled the investor call for Thursday, January 22, 2026.

Earnings Call Schedule

The company has set the earnings call timing and provided comprehensive access details for participants:

Dial-in Information

Alivus Life Sciences has provided multiple access options for domestic and international participants. The universal dial-in numbers for domestic participants are +91 22 6280 1564 and +91 22 7115 8394.

International Access Numbers

The company has arranged toll-free access for participants from various countries:

For participants who prefer toll numbers, the company has provided international toll options including Hong Kong (+852 30186877), Japan (+81 345899421), Singapore (+65 31575746), South Africa (+27 110623033), UK (+44 2034785524), and USA (+1 3233868721).

Regulatory Compliance and Contact Information

The earnings call announcement was filed under Regulation 30 with both BSE (Scrip Code: 543322) and NSE (Scrip Name: ALIVUS). Company Secretary and Compliance Officer Rudalf Corriea signed the notification on January 15, 2026.

For clarifications regarding the earnings call, participants can contact Diwakar Pingle at Diwakar.Pingle@in.ey.com or Runjhun Jain at Runjhun.Jain1@in.ey.com . The company has also provided a phone contact at +91 9820720993 and offers online pre-registration for the call.

Company Details

Alivus Life Sciences operates from its corporate office at Technopolis Knowledge Park, Andheri (E) Mumbai, with its registered office located in Solapur. The company maintains its investor relations through multiple communication channels and continues to provide regular updates to stakeholders about its financial performance and business developments.

Alivus Life Sciences Limited , a leading pharmaceutical company, has reported strong financial results for the second quarter of fiscal year 2026, demonstrating resilience in a dynamic market environment.

Key Financial Highlights

Revenue Growth Drivers

The company's 16% year-on-year revenue growth was primarily driven by:

1. Strong performance in the non-GPL (Glenmark Pharmaceuticals Limited) business, which grew by 39.70%.
2. Successful new product launches.
3. Robust growth in emerging markets, LATAM, Japan, Europe, and India (excluding GPL).

Margin Expansion

Alivus Life Sciences witnessed significant margin expansion in Q2 FY26:

• Gross margin improved to 57.70%, up 210 basis points year-on-year.
• EBITDA margin expanded to 33.00%, an increase of 480 basis points compared to the same quarter last year.

The margin improvement was attributed to rationalized input costs, new product launches, and a favorable product mix.

Segment Performance

• The non-GPL API business was the primary growth driver, with strong performances across multiple regions.
• The GPL segment experienced a decline due to customer inventory rationalization but is expected to recover in the second half of FY26.
• The CDMO (Contract Development and Manufacturing Organization) business showed mixed results but is anticipated to rebound in H2 FY26 with the addition of new projects and ramp-up of existing ones.

Future Outlook

Dr. Yasir Rawjee, Managing Director and CEO of Alivus Life Sciences, expressed confidence in the company's growth trajectory:

• Reaffirmed guidance of high single-digit revenue growth for FY26.
• Expects stronger performance in the second half of the year.
• Anticipates sustaining margins at around 30% despite the absence of PLI (Production Linked Incentive) benefits.

Strategic Initiatives

1. Capacity expansion projects at Solapur, Ankleshwar, and Dahej are progressing as planned.
2. The company maintains a robust pipeline with 586 DMF and CEP filings globally.
3. Focus on high-potent API portfolio development, with 26 products in the active grid representing a total addressable market of $66.00 billion.

Financial Position

Alivus Life Sciences continues to maintain a strong financial position:

• Remains debt-free.
• Cash and cash equivalents, including short-term investments, stood at ₹653.00 crores as of September 30, 2025.
• Generated cash flow from operations of ₹148.00 crores in H1 FY26.

The company's solid Q2 FY26 performance, coupled with its strategic initiatives and strong financial position, positions Alivus Life Sciences well for sustained growth in the coming quarters. Investors and market watchers will likely keep a close eye on the expected recovery in the GPL segment and the anticipated ramp-up in the CDMO business in the second half of the fiscal year.